Dignitana Stock Price, News & Analysis

Dignitana AB is a medical technology company headquartered in Lund, Sweden, specializing in the development and commercialization of innovative scalp cooling solutions for cancer patients undergoing chemotherapy. The company's flagship product, the DigniCap Scalp Cooling System, is an FDA-cleared medical device designed to minimize chemotherapy-induced hair loss by cooling the scalp during treatment sessions. This technology helps preserve patients' quality of life and psychological well-being during cancer therapy.

The company has continued to advance its technology with the introduction of DigniCap Delta, an enhanced scalp cooling system featuring solid-state cooling for precise temperature control and an improved single patient-use cap system. This next-generation device includes a flexible Cooling Wrap and adjustable Thermal Cap designed to optimize scalp cooling outcomes while improving ease-of-use for both patients and healthcare providers. Dignitana generates the majority of its revenue from the United States market and serves cancer treatment centers internationally.

Founded in 2007, Dignitana has established itself as a pioneer in the scalp cooling market, helping thousands of cancer patients retain their hair during chemotherapy. As of 2025, the company operates as a subsidiary of Paxman AB, another leader in the scalp cooling industry, creating a combined entity with enhanced capabilities to serve oncology patients worldwide.